ReviewPsychopharmacology2015
Application of cross-species PET imaging to assess neurotransmitter release in brain.
Review in Psychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 76 citations in OpenAlex.
- Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.Journal of psychopharmacology (Oxford, England) · 2018Pooled it
- AI-enabled multimodal neuroimaging for neurotransmitter mapping in normal aging and age-related disease.Frontiers in aging neuroscience · 2026Review
- Constructing the human brain metabolic connectome with MR spectroscopic imaging reveals cerebral biochemical organization.Nature communications · 2025Article
- Restoring consciousness with pharmacologic therapy: Mechanisms, targets, and future directions.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024Review
- Role of Biosynthesis and Catabolism of Neurotransmitters in Drug Discovery for Anxiety and Depression.Current pharmaceutical design · 2024Review
- Letting the little light of mind shine: Advances and future directions in neurochemical detection.Neuroscience research · 2022Review
- PET as a Translational Tool in Drug Development for Neuroscience Compounds.Clinical pharmacology and therapeutics · 2022Review
- The Synaptic Gene Study: Design and Methodology to Identify Neurocognitive Markers in Phelan-McDermid Syndrome andFrontiers in neuroscience · 2022Article
- Multi-scale neural decoding and analysis.Journal of neural engineering · 2021Review
- Recent Advances in In Vivo Neurochemical Monitoring.Micromachines · 2021Review
- Age-related GABAergic differences in the primary sensorimotor cortex: A multimodal approach combining PET, MRS and TMS.NeuroImage · 2021Article
- Inverse changes in raphe and cortical 5-HTSynapse (New York, N.Y.) · 2020Article
- Serotonin release measured in the human brain: a PET study with [Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- Methods for Quantifying Neurotransmitter Dynamics in the Living Brain With PET Imaging.Frontiers in physiology · 2020Review
- Dopamine, Opioids, and Positron Emission Tomography Imaging of the Human Brain: Contrasting Findings in Opioid Use Disorder and Healthy Volunteers.Biological psychiatry · 2019Article
- Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging.Medicinal research reviews · 2019Review
- Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?Frontiers in molecular neuroscience · 2019Review
- Innovative Molecular Imaging for Clinical Research, Therapeutic Stratification, and Nosography in Neuroscience.Frontiers in medicine · 2019Review
- In Vivo Chemical Monitoring at High Spatiotemporal Resolution Using Microfabricated Sampling Probes and Droplet-Based Microfluidics Coupled to Mass Spectrometry.Analytical chemistry · 2018Article
- Serotonin concentration enhancers at clinically relevant doses reduce [Translational psychiatry · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThis review attempts to summarize the current status in relation to the use of positron emission tomography (PET) imaging in the assessment of synaptic concentrations of endogenous mediators in the living brain.
objectivesAlthough PET radioligands are now available for more than 40 CNS targets, at the initiation of the Innovative Medicines Initiative (IMI) "Novel Methods leading to New Medications in Depression and Schizophrenia" (NEWMEDS) in 2009, PET radioligands sensitive to an endogenous neurotransmitter were only validated for dopamine. NEWMEDS work-package 5, "Cross-species and neurochemical imaging (PET) methods for drug discovery", commenced with a focus on developing methods enabling assessment of changes in extracellular concentrations of serotonin and noradrenaline in the brain.
resultsSharing the workload across institutions, we utilized in vitro techniques with cells and tissues, in vivo receptor binding and microdialysis techniques in rodents, and in vivo PET imaging in non-human primates and humans. Here, we discuss these efforts and review other recently published reports on the use of radioligands to assess changes in endogenous levels of dopamine, serotonin, noradrenaline, γ-aminobutyric acid, glutamate, acetylcholine, and opioid peptides. The emphasis is on assessment of the availability of appropriate translational tools (PET radioligands, pharmacological challenge agents) and on studies in non-human primates and human subjects, as well as current challenges and future directions.
conclusionsPET imaging directed at investigating changes in endogenous neurochemicals, including the work done in NEWMEDS, have highlighted an opportunity to further extend the capability and application of this technology in drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.